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A B S T R A C T
Incidence of obesity and hepatic steatosis is increasing worldwide. Almost one quarter of western countries popula-
tion suffer from non alcoholic fatty liver disease (NAFLD). The aim of this study was to investigate the frequency and
predictors of nonalcoholic steatohepatitis (NASH) in patients with unexplained alanine aminotransferase activity eleva-
tion (ALT), and therefore avoid unnecessary biopsies in cases of simple steatosis. Earlier studies provided different re-
sults and have not answered the question how to distinguish NASH from simple steatosis. Ultrasound (US), computed
tomography (CT) and magnetic resonance (MRI) can detect steatosis with great sensitivity level, but not NASH. This
study included 50 patients (18 women and 32 men) with mean age 43±9 years, and with defined selected biochemical,
anthropometric and hormone biomarkers. The average BMI was 27.1±3.81 (kg/m2), insulin resistance HOMA IR 3.89±
3.81. All patients underwent liver biopsy and NASH was staged by NASH activity score (NAS) from 1 to 8. Results are
compared to pathohistological finding as relevant method. The results show that 90% of patients (n=45) had NAFLD
(minimal stage at least), and 15 (30%) had nonalcoholic steatohepatitis (NASH). High triglyceride, low HDL and high
ferritin serum levels correspond with NASH. As in earlier studies, insulin resistance as basic mechanism of NAFLD and
NASH was confirmed.
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Introduction
Liver cirrhosis is frequent cause of death in western
countries1. Although chronic B and C hepatitis, as well as
alcoholism, are important causes of chronic liver disease,
in many patients etiology is still unclear1. Today, it is
known that non-alcoholic fatty liver disease (NAFLD) is
cause of substantial number of liver cirrhosis of un-
known origin (cryptogenic cirrhosis). NAFLD frequency
in general population is not precisely known, but is con-
sidered one of most frequent liver diseases, and strikes
up to 24% of population1–3. NAFLD is defined as liver
component of metabolic syndrome which includes hyper-
lipidemia, hypertension, obesity and glucose intoleran-
ce4,5. Histological characteristics of NAFLD are similar
to liver disease caused by alcohol; from steatosis (fatty
liver) and steatohepatitis (steatosis with parenchyma-
tous inflammation with or without focal necrosis) to dif-
ferent stages of fibrosis, including cirrhosis6. NAFLD ac-
tivity score (NAS) is in wide use7. Steatosis is mostly
macrovesicular, evenly distributed in lobuli. NASH is, in
fact, part of spectrum of NAFLD, more precisely, its ad-
vanced form. It comprises increased alanine transami-
nase activity (ALT) and histological appearance of alco-
hol hepatitis, but without alcohol usage in anamnesis8. A
»Two hit« theory was accepted as possible pathogenetic
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mechanism so far9. Increased trigliceride and free fatty
acids accumulation in liver causes steatosis (first hit),
and steatosis progression leads to steatohepatitis (NASH),
along with other factors such as oxidative stress, mito-
chondrial damage, fatty acids lipotoxicity (second hit)9.
Insulin resistance and hyperinuslinemia are primary pa-
thogenic factors in steatosis itself, besides eventual glu-
cose intolerance10–12.
Patients with NASH are most often without any
symptoms, but are by chance diagnosed with elevated
ALT activity8. Aspartate aminotransferase (AST) and
gamma glutamil-transpeptidase (GGT) activities can be
elevated as well8. Of all enzymes, ALT is connected to fat
accumulation the most, and therefore it is used as fat
liver disease marker13. Presence of liver steatosis in pa-
tients with metabolic syndrome and unexplained ALT el-





















Fig. 1. Distribution of participants according to NAS score.
TABLE 1
OUTPUT MEASURES FOR ALL SUBJECTS
X±SD Minimum Maximum
ESR (mm/h) 11.00±12.20 1.00 65.00
CRP (mg/L) 2.31±2.26 0.00 11.50
Leukocyte x10/L 6.00±1.66 3.70 10.50
Thrombocyte x10 /L 218.46±56.62 2.00 350.00
Erythrocyte x10/L 4.66±0.50 3.80 5.90
Hemoglobin (g/L) 139.50±13.70 117.00 179.00
P.V. (%) 58.04±44.19 1.00 116.00
Fe (mmol/L) 19.59±6.57 4.80 41.70
UIBC (mmol/L) 38.80±9.45 25.00 72.00
TIBC (mmol/L) 57.80±7.79 36.00 79.50
Ferritin (mg/L) 204.48±146.18 16.00 599.00
Bilirubin (umol/L) 16.49±8.43 6.40 48.30
Total cholesterol (mmol/L) 6.30±1.68 3.20 11.80
Triglyceride (mmol/L) 1.89±1.37 0.60 9.00
HDL (mmol/L) 1.25±0.62 0.60 5.00
IgG (g/L) 12.60±4.31 6.30 33.20
Fasting glucose (mmol/L) 5.91±1.67 3.90 11.80
HbA1c (%) 5.39±1.01 3.70 8.20
Creatinine (mmol/L) 84.88±17.30 56.00 154.00
AST (U/L) 70.38±83.16 25.00 586.00
ALT (U/L) 118.40±100.82 41.00 674.00
GGT (U/L) 135.80±84.80 10.00 450.00
AP (U/I) 83.39±28.90 39.00 185.00
LDH (U/L) 222.06±75.05 123.00 423.00
CK (U/L) 86.88±44.39 32.00 248.00
Total protein (g/L) 73.56±5.13 58.00 84.00
Albumin (g/L) 47.46±6.41 26.00 62.00
BMI (kg/m²) 27.18±3.10 23.00 34.00
AST/ALT 0.59±0.21 0.28 1.39
Insulin (mU/mL) 14.02±11.78 2.30 72.10
HOMA 3.83±3.41 0.60 19.50
X±SD: mean±standard deviation; ESR, erythrocyte sedimentation rate; CRP, C reactive protein; HDL, high-density lipoprotein;
CK, creatine kinase; BMI, body mass index; HOMA, homeostasis model assessment for insulin resistance=fasting glucose (mmol/L)
* fasting insulin (mmol/mL)/22.5
evation is diagnosed reliably by US, CT, MRI, and con-
firmed by liver biopsy14. Consistency of US and liver
biopsy diagnosed liver steatosis results are very weak
(47% sensitivity; 63% specificity; 11% positive predictive
value)15. On the other hand, negative predictive value of
US results is significant (92%), and with steatosis in over
half of hepatocytes, it rises to 96%15.
Patients and Methods
50 patients were included in this prospective study;
32 (64%) males and 18 (36%) females, mean age 43±9
years with elevated amino-transferase unclear origin.
Criteria for including was ALT>45 UI/L measured twice
in last six months. We excluded from our study all pa-
tients with alcohol consumption of more than 20 g per
week, with hepatic disease of known origin (cirrhosis,
primary biliary cirrhosis, primary sclerosing cholangitis,
actual or past viral hepatitis B or C, autoimmune liver
disease, Wilson’s disease, hereditary hemochromatosis,
a-1 antitrypsin deficiency) thyroid gland disease, hepa-
totoxic drugs therapy. Written informed consent was ob-
ligate for all participants. This study has obtained permit
by Hospital Ethics Committee in accordance with Hel-
sinki Declaration and lasted from January 2008 to De-
cember 2008 at the Department of Gastroenterology and
Hepatology of the University Hospital Centre Split, Split
and University Hospital Dubrava Zagreb, Croatia. Labo-
ratory tests consisted of erythrocyte sedimentation rate
(ES), CBC, serum liver function tests: aspartate-ami-
notransferase (AST), alanine-aminotransferase (ALT),
g-glutamil transpeptidase (GGT), lactate dehydogenase
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TABLE 2
DIFFERENCES BETWEEN SUBJECTS WITH NAS SCORE 5 (N=15) AND NAS SCORE <5 (N=35), STUDENT'S T-TEST






ESR (mm/h) 7.67±7.18 12.43±13.65 0.105
CRP (mg/L) 3.07±2.82 1.99±1.93 0.061
Leukocyte x10/L 6.52±1.89 5.78±1.52 0.076
Thrombocyte x10 /L 221.40±76.60 217.20±46.89 0.407
Hemoglobin (g/L) 143.80±17.32 137.66±11.63 0.074
P.V. (%) 58.15±43.96 58.00±44.93 0.496
Fe (mmol/L) 19.00±5.21 19.84±7.13 0.342
UIBC (mmol/L) 41.82±10.76 37.51±8.68 0.071
Ferritine (mg/L) 309.44±146.03 159.50±122.78 <0.001*
Bilirubin (umol/L) 18.04±9.73 15.83±7.87 0.201
Total cholesterol (mmol/L) 5.93±0.97 6.46±1.89 0.153
Triglyceride (mmol/L) 2.46±2.06 1.64±0.87 <0.026*
HDL (mmol/L) 0.98±0.19 1.36±0.70 <0.023*
IgG (g/L) 12.19±3.50 12.78±4.65 0.332
Fasting glucose (mmol/L) 6.22±1.76 5.78±1.63 0.200
HbA1c (%) 5.27±0.85 5.44±1.07 0.298
Creatinine (mmol/L) 87.33±12.77 83.83±18.99 0.259
AST (U/L) 60.87±4.842 74.46±95.68 0.301
ALT (U/L) 118.40±66.41 118.40±113.29 0.500
GGT (U/L) 130.00±112.43 138.29±71.68 0.378
AP (U/I) 81.73±24.23 84.12±31.04 0.397
LDH (U/L) 227.67±82.01 219.66±73.00 0.367
CK (U/L) 95.87±51.43 83.03±41.23 0.177
Total protein (g/L) 73.00±6.71 73.79±4.37 0.311
Albumin (g/L) 47.73±6.12 47.35±6.62 0.424
BMI (kg/m²) 31.07±2.43 25.51±1.38 <0.001*
AST/ALT 0.52±0.15 0.62±0.22 0.053
Insulin (mU/mL) 23.66±16.54 9.89±5.37 <0.001*
HOMA 6.49±4.37 2.69±2.12 <0.001*
X±SD: mean ± standard deviation, *: p<0.05; ESR, erythrocyte sedimentation rate; CRP, C reactive protein; HDL, high-density lipo-
protein; CK, creatine kinase; BMI, body mass index; HOMA, homeostasis model assessment for insulin resistance=fasting glucose
(mmol/L)
* fasting insulin (mmol/mL)/22.5
(LDH), bilirubin, creatine-phosphokinase (CPK), alka-
line phosphatase (AP), prothrombin time (PT), iron stu-
dies, fasting triglycerides and cholesterol profile, HDL,
LDL, ferritin, fasting glucose and insulin, glycolysed he-
moglobin A1c (HbA1c), protein, albumin, AST/ALT, C re-
active protein (CRP), creatinine, immunoglobulin G and
A (IgA and IgG). Insulin resistance with HOMA IR score
was calculated (fasting glucose (mmol/L)´fasting insulin
(mU/mL)/22.5), body mass index (BMI). Arterial hyper-
tension was assessed when RR was 140/60 mmHg or more.
Ultrasound (US) was performed with Toshiba SSA-325A.
All patients underwent ultrasound guided liver biopsy.
Quality of the biopsy material was assessed macroscopi-
cally. Two pathologists separately made patohystological
score of the nonalcoholic fatty liver disease with NAFLD
Activity Score (NAS)16. NAS score includes different
stages of steatosis, lobular inflammation and ballooning.
Steatosis stage 0 (<5% cells), stage 1 (5– 33%), stage 2
(33–66%), stage 3 (>66%). Lobular inflammation: stage 0
(none), stage 1 (<2 foci/200x field), stage 2 (2–4 foci/200x
field), stage 3 (>4 foci/200x field). Ballooning: stage 0
(none), stage 1 (few cells) and stage 2 (many cells/promi-
nent ballooning). Sum of each components NAS 5 mean
NASH, NAS <3 no evidence of NASH and NAS score 3 or
4 borderline/possible. The data were demonstrated as
X±SD. The difference between two groups was tested
with Students t-test for independent samples. The corre-
lation between variables was tested with Spearman’s
correlation test. The level of p<0.05 was considered sta-
tistically significant. The SPSS 14.0 program was used
for statistical analysis.
Results
All liver biopsies were adequate for pathohistological
analysis. Out of 50 included patients (age 43±9), BMI was
27.18±3.1, 22 (36%) patients were with arterial hyper-
tension. HOMA IR score is 3.83±3.41, ALT 118.4±100.82.
All biochemical and clinical parameters are demonstra-
ted in Table 1. Figure 1 shows the number of participants
depending on NAS score. Fifteen (30%) subjects had
NASH. The subjects were divided in two groups depend-
ing on NAS score: NAS score5 and NAS score <5. Dif-
ferences between two groups are demonstrated on Ta-
ble 2. There were differences between NASH and non-
-NASH group in ferritin concentration (295.83±159.13
vs. 187.08±138.85; p=0.026), in BMI (31.38±2.45 vs.
26.38±2.53; p<0.001), in insulin plasma level (26.36±
19.59 vs.11.67±8.06; p<0.001), in triglyceride (2.46±2.06
vs.1.64±0.87; p<0.026), in HDL (high density lipopro-
tein) (0.98±0.19 vs. 1.36±0.70; p<0.023) and in HOMA
(7.42±5.11 vs. 3.15±2.54; p<0.001). The NAS score was
correlated with biomarkers and clinical parameters, and
statistically significant correlations are demonstrated in
Table 3. The strong positive significant correlation be-
tween NAS score and BMI is demonstrated in Figure 2 as
a plot of linear regression.
Discussion
Obesity is a growing problem in the world with preva-
lence more than 20% of the USA population16. NASH, as
advanced form of NAFLD is reversible. Today we have a
liver biopsy as only reliable tool in diagnosis4. Special in-
terest of many studies is to find biomarkers of NASH and
distinguish it from steatosis. Prevalence of NASH in pa-
tients with chronic elevated amino alanine-transferase
in our study is 30%, and is similar with others. Strong
connection of some parameters as triglycerides, BMI, in-
sulin levels is confirmation of crucial role of insulin resis-
tance in pathogenesis of NASH. These results support
the evidence that insulin resistance is an important ele-
ment of NASH17,18. Obese patients with higher level of
triglycerides commonly have hepatocyte necroinflama-
tion. Insulin resistance is a sign of pre-diabetes and is ac-
companied by higher plasma insulin level. As a result of
this data HOMA levels are higher in NAS group than in
non-NASH. In our study 38% of patients have abnormal
HOMA IR (>2.6). Lesser HDL as protection factor in
NASH group shows that lobular necroinflammation is
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TABLE 3
STATISTICALLY SIGNIFICANT CORRELATIONS BETWEEN NAS












HDL – high-density lipoprotein; BMI – body mass indeks;
HOMA – insulin resistance=fasting glucose (mmol/L)
* fasting insulin (mmol/mL)/22.5
Fig. 2. Correlation between BMI and NASH score
(r=0.733, p<0.001).
relatively advanced liver disease which requires serious
therapy in time, before developing heart disease. Early
diagnosis is essential for preventing of cryptogenic cir-
rhosis and hepatocellular carcinoma. The finding that
patients with cryptogenic cirrhosis are at risk of NASH
now suggests that the end-stage disease may be greater
problem than previously recognized. End stage of
NAFLD liver disease is very common reason for liver
transplantation. ALT is not a good predictor of NASH.
Only patohistological diagnose can evaluate liver disease
stage and prognosis, and biopsy remains gold standard.
Different biomarkers in our study and elements of meta-
bolic syndrome together are inexpensive and help us to
detect NASH and make biopsy. Serum ferritin level has
been reported significantly higher in NASH, which may
reflect increased hepatic iron overload and enhanced oxi-
dative stress19. We have shown that high BMI, hypertri-
glyceridemia (with decreased HDL), high level of plasma
insulin and HOMA-IR can predict NASH. Biopsy in
non-NASH group of patients may be postponed or avoi-
ded.
Conclusion
High levels of plasma insulin, triglycerides, ferritin
with higher HOMA-IR and low HDL are good predictors
of NASH.
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PREDIKTORI NEALKOHOLI^NOG STEATOHEPATITISA ME\U PACIJENTIMA S POVE]ANOM
AKTIVNO[]U ALANIN AMINOTARNSFERAZE
S A @ E T A K
Debljina i nealkoholna masna bolest jetre su rastu}i svjetski problem. Gotovo ~etvrtina polulacije zapadnih zemalja
pati od masne bolesti jetre. Cilj ove studije bio je odrediti u~estalost i prediktore nealkoholnog steatohepatitisa u boles-
nika s nejasnim porastom aktivnosti alanin-aminotransferaze. Na taj na~in bi mogli izbje}i biopsiju jetre u slu~aju
obi~ne steatoze. Ranije studije su pokazale da ultrazvuk, kompjutorizirana tomografija i magnetska rezonanca pozdano
detektiraju steatozu, ali ne i nekroinflamaciju. Na{a studija je uklju~ila 50 bolesnika, 18 `ena i 32 mu{karca. Svima su
odre|eni razli~iti biokemijski antropometrijska i hormoski parametri te biopsija jetre. Svi rezultati su uspore|eni sa
patohistolo{kim kao relevantnim. NASH je imalo 30% bolesnika. Dokazano je da su povi{ene vrijednosti triglicerida,
feritina, inzulina i inzulinska rezistencij, uz visoki BMI pouzdani prediktori NASH-a. Rezultati studije nam omogu-
}avaju da kombinacijom ovih parametara i ultrazvuka, izbjegnemo nepotrebne biopsije jetre.
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